C
19.16
0.31 (1.64%)
| Previous Close | 18.85 |
| Open | 18.97 |
| Volume | 300,508 |
| Avg. Volume (3M) | 431,346 |
| Market Cap | 553,193,280 |
| Price / Sales | 1.82 |
| Price / Book | 1.36 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Profit Margin | -1.46% |
| Operating Margin (TTM) | -31.74% |
| Diluted EPS (TTM) | -0.190 |
| Quarterly Revenue Growth (YOY) | 20.60% |
| Total Debt/Equity (MRQ) | 5.87% |
| Current Ratio (MRQ) | 9.37 |
| Operating Cash Flow (TTM) | 65.67 M |
| Levered Free Cash Flow (TTM) | 44.64 M |
| Return on Assets (TTM) | -1.80% |
| Return on Equity (TTM) | -1.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Castle Biosciences, Inc. | Mixed | Bullish |
AIStockmoo Score
-0.6
| Analyst Consensus | 2.5 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.5 |
| Average | -0.60 |
|
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Core |
| % Held by Insiders | 2.98% |
| % Held by Institutions | 93.02% |
| 52 Weeks Range | ||
| Median | 37.00 (93.11%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 09 Sep 2025 | 37.00 (93.11%) | Buy | 24.65 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |